After 30 cases of thrombosis in the country following injections of AstraZeneca’s anti-covid vaccine, the University of Oxford in the United Kingdom announces that it is suspending its clinical trials of the product in children aged 6 to 17 .
The University of Oxford announced on April 6 that it was suspending trials on children of the Covid-19 vaccine it had developed with the Anglo-Swedish laboratory AstraZeneca, pending the opinion of the regulator British.
“While there are no concerns regarding the safety of the pediatric clinical trial, we await further information from the MHRA,” the UK regulator, “on the rare cases of thrombosis which have been reported in adults, before proceeding with new vaccinations in the trial, ”the university said in a statement.
“Parents and children should continue to attend scheduled visits and can contact the sites where the trial is being held if they have any questions,” the UK university added.
The MHRA is investigating reports of blood clots in patients who have received the AstraZeneca vaccine. Seven fatal cases have been identified in the United Kingdom out of a total of 30 identified cases, the regulator said on April 3, while more than 18 million doses of the AstraZeneca vaccine were administered in the country. MHRA official June Raine has since asserted that people should “continue to be vaccinated when instructed to do so.”
The risk / benefit balance weighs “largely” in favor of AstraZeneca, says WHO
An official of the World Health Organization (WHO), Rogerio Pinto de Sa Gaspar, estimated on April 6 that the risk / benefit balance continued to weigh “largely” in favor of the use of the anti-Covid vaccine of AstraZeneca.
Earlier today, an official from the European Medicines Agency (EMA) mentioned the existence of a “link” between the AstraZeneca vaccine and the cases of thrombosis observed after its administration, in an interview with the Italian daily. Il Messaggero published April 6.
The European agency immediately clarified that its security committee “has not yet reached a conclusion and [que] the review is currently underway ”.
For several weeks, suspicions have appeared on possible serious and rare side effects, after the observation in people vaccinated with AstraZeneca of cases of atypical thrombosis.
As a precaution, several countries have decided to no longer administer this vaccine below a certain age, such as France, Germany and Canada. Norway and Denmark have even suspended its use for now. For its part, AstraZeneca assured in March that there was “no evidence of aggravated risk”, and assured Saturday that “patient safety” was its “main priority”.